The 32nd Conference on Retroviruses and Opportunistic Infections (CROI) is being held on March 9 -12, 2025, in San Francisco, California. Learn more about CROI 2025 and the exciting work of our CHIPTS scientists featured at the conference below.
What is CROI 2025?
CROI 2025 provides a forum for scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. CROI is the preeminent HIV research meeting in the world and includes up to 4,000 HIV research and care leaders internationally. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research.
CHIPTS at CROI 2025
Several CHIPTS scientists will be sharing exciting research findings and project updates at CROI 2025, contributing to the dissemination of crucial information that advances HIV prevention and treatment initiatives globally. We are delighted to highlight workshops, oral abstracts, and poster abstracts featuring the important work of our CHIPTS scientists.
Sunday, March 9, 2025
Raphael Landovitz (Moderator)
Workshop 01 – Scott M. Hammer Workshop for New Investigators and Trainees
Session Start: 8:30 AM (San Francisco Ballroom B)
Monday, March 10, 2025
Poster Session H1 – HIV Resistance to bNAbs, Cabotegravir, GS 1720, and Other Agents
Session Start: 2:30 PM (Poster Hall)
725 – Effect of SNG001, Inhaled IFN-β1a, on SARS-CoV-2 Diversity and Evolution
Poster Session K2 – Hypertension
Session Start: 2:30 PM (Poster Hall)
820 – No Increased Risk for Hypertension With CAB-LA Compared to TDF/FTC for PrEP: Results From HPTN 084
Poster Session-M1 – PASC: Natural History and Classification Systems
Session Start: 2:30 PM (Poster Hall)
921 – Assessing the Burden of Long COVID in Persons With HIV Using the RECOVER Scoring System
Poster Session T1 – Still Here: Syphilis
Session Start: 2:30 PM (Poster Hall)
1249 – Risk Factors for Incomplete Treatment for Syphilis in Pregnant Oral PrEP Users in South Africa
Tuesday, March 11, 2025
Oral Abstract Session 06 – Immunology and Vaccines
Session Start: 10:00 AM (San Francisco Ballroom C)
142 – Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Dvora L. Joseph Davey, Kathryn L. Dovel, and Thomas Coates
Oral Abstract Session 08 – New Frontiers in STI Prevention
Session Start: 10:00 AM (San Francisco Ballroom D)
166 – Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Kathryn L. Dovel
Poster Session Q01 – The HIV Care and Prevention Cascades: Novel Insights
Session Start: 2:30 PM (Poster Hall)
1086 – High Burden of Untreated HIV in Malawian Fishermen: Prospective Data From a Cluster Randomized Trial
Poster Session T4 – Global STI Epidemiology
Session Start: 2:30 PM (Poster Hall)
1265 – Diagnostic Screening and Treatment of Curable STIs in Pregnancy and Impact on Pregnancy Outcomes
Wednesday, March 12, 2025
Oral Abstract Session 11 – Gaps and Solutions in the HIV Response
Session Start: 10:00 AM (San Francisco Ballroom A)
183 – Preliminary Efficacy for HPTN 094: 26-Week RCT of Integrated Strategies for People Who Inject Drugs
Kathryn L. Dovel and Thomas Coates
Oral Abstract Session 11 – Gaps and Solutions in the HIV Response
Session Start: 10:00 AM (San Francisco Ballroom A)
185 – Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial
Oral Abstract Session 12 – Expanding the Prevention Toolbox
Session Start: 10:00 AM (San Francisco Ballroom D)
192 – ImPrEP CAB Brasil: Enhancing PrEP Coverage With CAB-LA in Young Key Populations
193 – Estimation of Prevention-Effective CAB-LA Concentrations Among MSM/TGW in HPTN 083
197 – Response to HIV Treatment After Long-Acting Cabotegravir Preexposure Prophylaxis in HPTN 083
Poster Session F3 – Pharmacokinetics in the Real World: Long-Acting Drugs, Alternative Matrices, and Adherence
Session Start: 2:30 PM (Poster Hall)
653 – TFV-DP Is Associated With Baseline Virologic Suppression in PWH on TAF: Results From ACTG A5359
Poster Session G3 – ART in Vulnerable and Treatment – Experienced Populations
Session Start: 2:30 PM (Poster Hall)
692 – A5359: Decreasing Oral Induction Duration in Support of LAI ART Use With Hardly Reached Populations
Poster Session G5 – Antiviral Therapy for SARS-CoV-2
Session Start: 2:30 PM (Poster Hall)
713 – SARS-CoV-2 Ensitrelvir Resistance-Associated Mutations in Phase III Randomized Clinical Trial
Dvora L. Joseph Davey and Kathryn L. Dovel
Poster Session O5 – HIV Acquisition and Prevention During Pregnancy and Breastfeeding
Session Start: 2:30 PM (Poster Hall)
1009 – PrEP Adherence and Acceptability of Urine Tenofovir Testing in Pregnant and Postpartum Women
Steve Shoptaw and Pamina M. Gorbach
Poster Session Q10 – HIV and Substance Use
Session Start: 2:30 PM (Poster Hall)
1145 – Unstable Housing, Methamphetamine Use, and HIV Incidence Among Racial and Ethnic Minority Men
1146 – Substance Use Is Associated With Higher HIV Viral Load and Reduced Viral Suppression in 6 US Cohorts
Poster Session R3 – Challenging and Innovative HIV Testing
Session Start: 2:30 PM (Poster Hall)
1193 – Use of DNA Profiling to Resolve Discrepant HIV Tests in the Setting of Injectable Cabotegravir PrEP